Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning.
about
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphomaSalvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: a dual center retrospective analysis.Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.Immunoregulatory functions of mTOR inhibition.Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms.Bactericidal/permeability-increasing protein (rBPI21) and fluoroquinolone mitigate radiation-induced bone marrow aplasia and death.A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL).Combining allogeneic immunotherapy with an mTOR inhibitor for advanced renal cell carcinoma.Allogeneic hematopoietic cell transplantation: the state of the artA randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation.Targeted therapy in lymphoma.Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis.A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphomaStrategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantationA large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome.(90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma.Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids.A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients.Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant.Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after.Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host diseaseHigh-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses.Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control.Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome.The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trialThe combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate.Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantation.Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future.Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHDComparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantatThe addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial.Relapse after allogeneic stem cell transplantationMammalian target of rapamycin as a target in hematological malignancies.Stem cell transplantation for indolent lymphoma: a reappraisal.Evi1 forms a bridge between the epigenetic machinery and signaling pathways.Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma.Rapamycin-resistant effector T-cell therapy.Thinking out of the box--new approaches to controlling GVHD.Biological relevance of Hsp90-binding immunophilins in cancer development and treatment.
P2860
Q24607479-F2CC0298-6EEB-4A5F-96F8-55AD9E13E077Q33416874-AE027F4B-30FB-4F99-ADF7-A6E6CF120F40Q33685495-5C5DEB46-CB49-4D9D-A0A3-4A6667345434Q33761278-62CD46A2-D2FF-4E50-AB9C-31B96D315A5CQ33771667-BC40E571-C84B-418E-99EC-839582BD23C1Q33896849-07551C34-2E9B-4922-8DBF-B5675BB2CC55Q33924570-0A5345C9-10E2-4986-9499-4F84F0380E0FQ34067551-7F0513EF-8F1F-4A14-A4C8-285A0B3EDCF8Q34145155-5299FD0E-1168-43B6-9724-F2465B5C1E3EQ34272554-26AB629C-2C3F-42EB-8253-94CED72079A9Q34413686-A5EC3294-1AC7-4B37-A294-6D83E03079FDQ34451427-C8BCB6AF-D55A-49A8-9D87-88A07EBD4402Q34617756-BF8CA6BB-6B9A-4C4D-809E-39ECBB71ABD3Q34622755-F6E9DD4D-607B-480B-BD69-D1C214568B23Q34827332-AEFDD782-7ECC-4FE4-BCC2-587C9FE97112Q35064713-67DAAA17-5826-4A94-BD39-59FC9617B85FQ35115650-050BD7BB-BE1E-4225-9D82-466BE28E57F9Q35193740-612724BD-DB28-43AE-83A4-16E9305658CDQ35218515-ECA8536E-555E-4323-96AB-63CD1180024CQ35231363-7C7A3227-7A31-4440-83D1-3345E6CDC85FQ35446852-2C1AE85A-2C03-4198-AA22-AF0CF719F889Q35800856-47532827-E320-4AD5-B25B-009668A28EAFQ36117735-07DFE82B-3E50-41A2-8C31-B4581062855BQ36231758-715A4619-FD57-4F68-97E9-26F9A3007254Q36460415-E9656204-EA1B-43E5-BB72-C3544186E350Q36734547-5BFCD8FE-4850-4F21-BD98-EF4D22A1B0A9Q36862464-7398EF3C-FA9B-4DCE-9BE3-71E25ACF2CD3Q36868082-4D156850-EB11-467B-A007-AE50B2E8A18EQ36980277-7488E67A-7E78-4F52-9190-95A054CEED69Q37000189-2B71A05C-2AB8-4F9F-BDC7-3004AB521807Q37238884-0861514D-891A-4D01-8A8D-DCBF4A773388Q37670062-C93623FE-9E38-420B-971F-DA12BB6A430AQ37810125-9FDD01AA-92D0-4FD5-8A9B-74313A91E6EAQ37866136-6AD89F6E-A3E5-4613-8F76-FCE70E688039Q37884884-F2DFE1D9-6E4A-4463-BE35-772D4BC3D0F2Q37906986-55A043CA-7D3C-46FC-BB18-F56445F92B5FQ37938531-919B893A-70AD-4A88-ABC5-9899A9C5C525Q38170502-B9A22F58-EBC4-4CB9-970C-F35FBBF304E7Q38175862-DACED1D1-4BF8-4FD4-8520-720E2CD05E79Q38371280-EDF256E8-EEEA-4F83-BB18-BDE2AD587C3C
P2860
Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Improved survival in lymphoma ...... educed-intensity conditioning.
@en
type
label
Improved survival in lymphoma ...... educed-intensity conditioning.
@en
prefLabel
Improved survival in lymphoma ...... educed-intensity conditioning.
@en
P2093
P2860
P356
P1476
Improved survival in lymphoma ...... educed-intensity conditioning.
@en
P2093
Ann S LaCasce
Arnold S Freedman
Corey S Cutler
David C Fisher
Edwin P Alyea
Eric D Jacobsen
George P Canellos
Haesook T Kim
Jennifer R Brown
John Koreth
P2860
P304
P356
10.1200/JCO.2008.17.7279
P407
P577
2008-11-10T00:00:00Z